Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Concordia Healthcare Corp. T.CXR.R

TSX:CXR.R - Post Discussion

Concordia Healthcare Corp. > RBC investment Thesis..even low target is higer then SP
View:
Post by fundtrader on Oct 17, 2016 2:14pm

RBC investment Thesis..even low target is higer then SP

Target price/base case Our $14 price target is based on the average of our EV/EBITDA valuation and DCF analysis. Applying a 7.3x multiple to our 2017 Adj. EBITDA forecast of ~$499MM generates a value of $12.04. Our DCF value (11.0% WACC and a -2% terminal growth rate) equates to $15.74. The average of our EV/EBITDA and DCF values is $13.89, hence our $14 price target. There are no further acquisitions included in our base case. We assume that Photofrin is approved for bile duct cancer in 2018.
Upside scenario Our $27 upside scenario utilizes a 8.0x multiple on 2017E Adj. EBITDA of $550MM, equating to a value of $26.38. Our DCF value equates to $27.12. The average of our EV/EBITDA and DCF values is $26.75, rounded to our $27 upside value. This scenario utilizes a 1% terminal growth rate and higher multiple plus incrementally higher EBITDA to reflect stronger organic growth. We also assume that Photofrin is approved for bile duct cancer in 2018.
Downside scenario Our $4 downside scenario utilizes a 7.0x multiple on 2017E Adj. EBITDA of $460MM, generating a value of $3.82. This scenario assumes no new approvals for Photofrin and lowerthan-anticipated demand for the portfolio. We also assume increased AMCo competition and lower Donnatal demand.
Comment by Craigbad on Oct 17, 2016 2:19pm
Not going to be pretty when they factor in increased debt, increased interest payments and hopefully reduce the multiple. The haven't updated target prices to reflect the note issue. Stay tuned! Lol
Comment by LaticelnExile on Oct 17, 2016 2:41pm
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities